60,762 Shares in AbbVie Inc. $ABBV Bought by North Dakota State Investment Board

North Dakota State Investment Board bought a new position in shares of AbbVie Inc. (NYSE:ABBV) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund bought 60,762 shares of the company’s stock, valued at approximately $13,884,000. AbbVie makes up about 0.5% of North Dakota State Investment Board’s investment portfolio, making the stock its 23rd biggest position.

Several other institutional investors and hedge funds have also recently bought and sold shares of ABBV. Elyxium Wealth LLC boosted its position in shares of AbbVie by 3.4% during the 4th quarter. Elyxium Wealth LLC now owns 4,867 shares of the company’s stock worth $1,112,000 after acquiring an additional 161 shares in the last quarter. United Bank boosted its position in shares of AbbVie by 23.1% during the 4th quarter. United Bank now owns 1,353 shares of the company’s stock worth $309,000 after acquiring an additional 254 shares in the last quarter. Abacus Wealth Partners LLC boosted its position in shares of AbbVie by 162.9% during the 4th quarter. Abacus Wealth Partners LLC now owns 12,790 shares of the company’s stock worth $2,922,000 after acquiring an additional 7,925 shares in the last quarter. Soltis Investment Advisors LLC boosted its position in shares of AbbVie by 55.0% during the 4th quarter. Soltis Investment Advisors LLC now owns 34,077 shares of the company’s stock worth $7,786,000 after acquiring an additional 12,096 shares in the last quarter. Finally, Ranch Capital Advisors Inc. boosted its position in shares of AbbVie by 3.1% during the 4th quarter. Ranch Capital Advisors Inc. now owns 10,871 shares of the company’s stock worth $2,484,000 after acquiring an additional 322 shares in the last quarter. 70.23% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie’s Q1 results were supported by strong sales of Skyrizi and Rinvoq, which helped offset ongoing Humira declines and boosted the company’s 2026 guidance. Article: How Important Are Skyrizi and Rinvoq to AbbVie’s Q1 Results?
• Positive Sentiment: Analysts have turned more optimistic on AbbVie’s earnings power, with Erste Group raising FY2027 EPS estimates and the company’s long-term pipeline still viewed favorably.
• Positive Sentiment: Recent commentary highlighted AbbVie as a potentially better growth story than AstraZeneca because of its valuation, dividend profile, and pipeline strength. Article: Which Pharma Giant Offers Better Growth: AstraZeneca or AbbVie?

AbbVie Stock Up 0.1%

Shares of NYSE ABBV opened at $210.54 on Monday. The stock has a market cap of $371.97 billion, a PE ratio of 103.71, a price-to-earnings-growth ratio of 0.73 and a beta of 0.32. AbbVie Inc. has a 52-week low of $180.25 and a 52-week high of $244.81. The business has a 50-day moving average price of $210.27 and a 200 day moving average price of $220.05.

AbbVie (NYSE:ABBV) last announced its earnings results on Wednesday, April 29th. The company reported $2.65 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.59 by $0.06. The firm had revenue of $15 billion during the quarter, compared to analysts’ expectations of $14.72 billion. AbbVie had a negative return on equity of 576.45% and a net margin of 5.79%.The business’s revenue was up 12.4% on a year-over-year basis. During the same period in the prior year, the firm earned $2.46 EPS. Sell-side analysts anticipate that AbbVie Inc. will post 14.3 earnings per share for the current year.

AbbVie Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th were paid a dividend of $1.73 per share. The ex-dividend date of this dividend was Wednesday, April 15th. This represents a $6.92 annualized dividend and a yield of 3.3%. AbbVie’s dividend payout ratio is currently 340.89%.

Analyst Upgrades and Downgrades

ABBV has been the subject of several analyst reports. Citigroup lowered their price objective on AbbVie from $235.00 to $230.00 and set a “neutral” rating for the company in a research report on Tuesday, January 27th. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of AbbVie in a research report on Thursday, February 5th. Royal Bank Of Canada initiated coverage on AbbVie in a research report on Tuesday, February 24th. They set an “outperform” rating and a $260.00 price objective for the company. Barclays began coverage on AbbVie in a research report on Thursday, February 19th. They set an “overweight” rating and a $275.00 price objective for the company. Finally, The Goldman Sachs Group reissued a “neutral” rating and issued a $223.00 target price on shares of AbbVie in a research report on Wednesday, January 28th. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $253.43.

Insider Activity at AbbVie

In other AbbVie news, SVP David Ryan Purdue sold 5,230 shares of the company’s stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the completion of the sale, the senior vice president directly owned 2,654 shares of the company’s stock, valued at $619,868.24. This represents a 66.34% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Perry C. Siatis sold 22,381 shares of the company’s stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total value of $5,147,630.00. Following the sale, the executive vice president directly owned 38,137 shares of the company’s stock, valued at approximately $8,771,510. This represents a 36.98% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 0.06% of the stock is owned by corporate insiders.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.